The leading asset purchase deals are sorted according to the most active dealmakers in asset purchase, and the deal activities in big pharma and big biotech
Albany, NewYork (PRWEB) February 10, 2015
ResearchMoz has recently added a research document “Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics” to its collection of detailed, analytical market research reports. The 1,445-page research report provides a comprehensive flow that fully elaborates the asset purchasing deals that have been made since 2009. The report offers full access to large volumes of data about agreements that have been made by the world’s leading biopharma companies.
Read Full Report With TOC @ http://www.researchmoz.us/asset-purchase-terms-and-agreements-in-pharma-biotech-and-diagnostics-report.html
All the asset purchase deals that have been made public since 2009 have been included in the report. The data is exactly as recorded in the Current Agreements deals and databases of alliances. This also includes terms of finance if they are made available. The report also provides links to the online copies of actual contract documents pertaining to asset purchases, exactly as the deal makers have submitted to the Securities Exchange Commission.
The magnitude of value that each partner can derive from a deal can be found out through the contract documents. They are included in the report, and they provide the user with solutions to various issues regarding a prospective partner’s flexibility on a wide range of critical issues.
The report on asset purchase deals provides some key benefits, such as a complete list of asset purchase deals that have been made, ordered in a categorical manner from A to Z, technology focus, therapy type, development phase, deal value, and deal type.
An access to more than 1,000 asset purchase deals can be gained through the report. These are the deals that have made their way into the global biopharma industry. The report also provides contract documents whenever available.
Some of the key case studies that have been elaborated upon in the report include QLT – Valeant Pharmaceuticals, BioTime Acquisition Corporation– Geron Corporation, and Enzon Pharmaceuticals – Sigma-Tau.
The trends in asset purchase deal making, as explained by the report, include the beginning of royalty asset purchase deals, the role of IP auction houses in asset purchase deals, the leading players in IP auction, and the outlook of asset purchase agreements.
The leading asset purchase deals are sorted according to the most active dealmakers in asset purchase, and the deal activities in big pharma and big biotech.
Request A Sample @ http://www.researchmoz.com/enquiry.php?type=sample&repid=93020
The initial passages of the report are divided into chapters of seven, each of which provides progressive information on asset purchase deals. Chapter one, for instance, gives an introduction to the report. Chapter five includes a descriptive list of 50 of the biggest companies in asset purchasing. They are explained in terms of a comprehensive list of deals in asset purchasing that are visible in the public domain.
The report, in conclusion, offers all that a user or a prospective dealmaker needs to learn about alliances and asset purchases.
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453